New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
08:07 EDTESI, ABBV, ABT, FII, NCIT, DELLAbbVie to join S&P 100, 500 in place of Dell, Federated Investors
S&P Dow Jones Indices announced last night that it will make the following changes to the S&P 100, 500, MidCap 400 and SmallCap 600 indices after the close of trading on Monday, December 31: AbbVie (ABBV) will replace Dell (DELL) in the S&P 100, and Federated Investors (FII) in the S&P 500. Federated will replace ITT Educational Services (ESI) in the S&P MidCap 400, and ITT Educational Services will replace NCI Inc. (NCIT) in the S&P SmallCap 600. S&P 100 and 500 constituent Abbott (ABT) is spinning off AbbVie in a transaction expected to be completed after the close of trading on December 31. Abbott will remain in the S&P 100 and 500.
News For ABBV;DELL;FII;ESI;NCIT;ABT From The Last 14 Days
Check below for free stories on ABBV;DELL;FII;ESI;NCIT;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2014
09:35 EDTABTAbbott: We have plenty of cash for M&A activity, not constrained on borrowing
09:15 EDTABTAbbott sees pace of EPS growth and sales to accelerate throughout FY14
Subscribe for More Information
09:14 EDTABTAbbott sees Q2 EPS 50c-52c, consensus 51c
Sees Q2 sales growth in low to mid single digits, consensus $5.54B.
09:13 EDTABTAbbott sees accelerating sales growth in 2H14
Subscribe for More Information
07:49 EDTABTAbbott expects to increase global capacity to meet demand in 2014
Expects three new manufacturing facilities scheduled to come on line in China, India and the U.S. in Q2. Adult Nutrition remains on track to achieve an operating margin ratio of more than 20 percent of sales by 2015.
07:47 EDTABTAbbott completes enrollment in U.S., China, Japan in Absorb regulatory trials
Subscribe for More Information
07:46 EDTABTAbbott backs FY14 adjusted EPS $2.16-$2.26, consensus $2.20
07:46 EDTABTAbbott reports Q1 adjusted EPS 41c, consensus 36c
Subscribe for More Information
April 15, 2014
15:19 EDTABTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:14 EDTABTEarnings Preview: Abbott's established pharmaceuticals sales in focus
Subscribe for More Information
09:22 EDTABBVAbbVie initiates Phase III clinical trial of veliparib in lung cancer
AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib or ABT-888, in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer. The trial will compare patients randomized to receive either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo. The trial will recruit approximately 900 patients.
April 14, 2014
17:31 EDTABBVAbbVie stock could reach $55, Barron's says
Subscribe for More Information
16:54 EDTESIPoint72 raises passive stake in ITT Educational to 5.7% from 5.0%
Subscribe for More Information
09:05 EDTABTAbbott announces FDA clearance for test to diagnose diabetes
Subscribe for More Information
07:45 EDTABBVAbbVie defended at BMO Capital
Subscribe for More Information
April 12, 2014
19:23 EDTABBVEnanta reports detailed results from Turquoise ll study
Enanta Pharmaceuticals (ENTA) announced that detailed results from AbbVie’s (ABBV) pivotal phase 3 TURQUOISE-II study, will be presented as a late-breaking oral presentation at the International Liver Congress, ILC, which is the 49th Annual Meeting of the European Association for the Study of the Liver, EASL. Results from the TURQUOISE-II study were featured in the ILC press conference and were published on-line in the New England Journal of Medicine. The TURQUOISE-II study reports results from AbbVie’s investigational three direct-acting antiviral regimen containing ABT-450, Enanta’s lead protease inhibitor discovered through Enanta’s collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's three direct-acting antiviral regimen with ribavirin, RBV, in adult patients with genotype 1, GT1, chronic hepatitis C virus, HCV, infection with compensated liver cirrhosis. Patients achieved sustained virologic response rates 12 weeks post-treatment, SVR12, of 91.8% and 95.9% in the 12-week and 24-week treatment arms, respectively. Patients in the study were either new to therapy or treatment-experienced, failed previous treatment with pegylated interferon and RBV.
April 11, 2014
05:27 EDTABBVEnanta announces results for partner AbbVie's HCV studies
Subscribe for More Information
05:24 EDTABBVAbbVie announces 96% sustained virologic response rates in HCV study
Subscribe for More Information
April 10, 2014
08:34 EDTABTAbbott completes enrollment of Absorb clinical trials in U.S., Japan and China
Subscribe for More Information
April 9, 2014
11:43 EDTABT, ABBVGilead defended by analysts after recent pullback
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use